Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study

被引:62
作者
Razo, Christian [1 ,2 ]
Welgan, Catherine A. [3 ]
Johnson, Catherine O. [1 ]
McLaughlin, Susan A. [1 ]
Iannucci, Vincent [1 ]
Rodgers, Anthony [4 ]
Wang, Nelson [4 ]
LeGrand, Kate E. [1 ]
Sorensen, Reed J. D. [1 ]
He, Jiawei [1 ]
Zheng, Peng [1 ,2 ]
Aravkin, Aleksandr Y. [1 ,2 ,5 ]
Hay, Simon, I [1 ,2 ]
Murray, Christopher J. L. [1 ,2 ]
Roth, Gregory A. [1 ,2 ,6 ]
机构
[1] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia
[5] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA
[6] Univ Washington, Div Cardiol, Seattle, WA 98195 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
CONVERTING-ENZYME-INHIBITOR; PLACEBO-CONTROLLED TRIAL; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR EVENTS; DOUBLE-BLIND; J-CURVE; HYPERTENSION; MORTALITY; RAMIPRIL; RISK;
D O I
10.1038/s41591-022-01974-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A systematic review using the burden of proof meta-analytic method found a significant harmful effect between high systolic blood pressure and ischemic heart disease. High systolic blood pressure (SBP) is a major risk factor for ischemic heart disease (IHD), the leading cause of death worldwide. Using data from published observational studies and controlled trials, we estimated the mean SBP-IHD dose-response function and burden of proof risk function (BPRF), and we calculated a risk outcome score (ROS) and corresponding star rating (one to five). We found a very strong, significant harmful effect of SBP on IHD, with a mean risk-relative to that at 100 mm Hg SBP-of 1.39 (95% uncertainty interval including between-study heterogeneity 1.34-1.44) at 120 mm Hg, 1.81 (1.70-1.93) at 130 mm Hg and 4.48 (3.81-5.26) at 165 mm Hg. The conservative BPRF measure indicated that SBP exposure between 107.5 and 165.0 mm Hg raised risk by 101.36% on average, yielding a ROS of 0.70 and star rating of five. Our analysis shows that IHD risk was already increasing at 120 mm Hg SBP, rising steadily up to 165 mm Hg and increasing less steeply above that point. Our study endorses the need to prioritize and strengthen strategies for screening, to raise awareness of the need for timely diagnosis and treatment of hypertension and to increase the resources allocated for understanding primordial prevention of elevated blood pressure.
引用
收藏
页码:2056 / +
页数:25
相关论文
共 72 条
[1]   Major clinical trials of hypertension - What should be done next? [J].
Alderman, MH ;
Arnett, DK ;
Bakris, GL ;
Black, HR ;
Boerwinkle, E ;
Califf, RM ;
Cushman, WC ;
Cutler, J ;
Davis, BR ;
Devereux, RB ;
Ferdinand, K ;
Fleg, JL ;
Fournier, A ;
Furberg, CD ;
Giles, TD ;
Gottdiener, JS ;
Grimm, RH ;
Hyman, DJ ;
Jamerson, KA ;
Kostis, JB ;
Krauss, RM ;
Leenen, FHH ;
Levey, AS ;
Levy, D ;
MacMahon, S ;
Oparil, S ;
Probstfield, JL ;
Psaty, BM ;
Roccella, E ;
Salive, M ;
Schwartz, WB ;
Svetkey, L ;
Throckmorton, D ;
Turner, ST ;
Velletri, P ;
Wright, J .
HYPERTENSION, 2005, 46 (01) :1-6
[2]  
AMERY A, 1985, LANCET, V1, P1349
[3]  
[Anonymous], 1991, JAMA, V265, P3255
[4]  
[Anonymous], 1993, Stroke, V24, P543
[5]   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[6]   Treatment of hypertension in patients 80 years of age or older [J].
Beckett, Nigel S. ;
Peters, Ruth ;
Fletcher, Astrid E. ;
Staessen, Jan A. ;
Liu, Lisheng ;
Dumitrascu, Dan ;
Stoyanovsky, Vassil ;
Antikainen, Riitta L. ;
Nikitin, Yuri ;
Anderson, Craig ;
Belhani, Alli ;
Forette, Francoise ;
Rajkumar, Chakravarthi ;
Thijs, Lutgarde ;
Banya, Winston ;
Bulpitt, Christopher J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (18) :1887-1898
[7]  
Benavente OR, 2013, LANCET, V382, P506
[8]  
Bosch J, 2006, NEW ENGL J MED, V355, P1551
[9]  
Braunwald E, 2004, NEW ENGL J MED, V351, P2058
[10]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869